What is the diagnosis and treatment for High Altitude (HA) Cerebral Edema (HACE)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

High altitude cerebral edema (HACE) is a life-threatening condition requiring immediate descent to lower altitude and medical treatment, as highlighted in the most recent study 1.

Key Considerations

  • Dexamethasone should be administered at 8mg initially, followed by 4mg every 6 hours, as part of the treatment protocol.
  • Supplemental oxygen should be provided to maintain oxygen saturation above 90%, which is crucial for managing the condition.
  • If available, use of a portable hyperbaric chamber (Gamow bag) can temporarily simulate descent when physical descent is impossible, as noted in previous studies 1.
  • Acetazolamide at 250mg twice daily may help with acclimatization but is not a primary treatment for established HACE, according to the evidence 1.

Prevention Strategies

  • Gradual ascent (no more than 300-500 meters per day above 3000 meters) is essential to prevent HACE.
  • Adequate acclimatization periods are critical, and prophylactic acetazolamide may be considered for those with a previous history of HACE, as suggested by the guidelines 1.

Clinical Presentation

  • HACE typically develops after acute mountain sickness symptoms and presents with confusion, ataxia, and altered mental status, which can progress rapidly to coma and death within 24 hours if left untreated, emphasizing the need for prompt recognition and action 1.

Pathophysiology

  • The condition results from brain swelling due to hypoxia-induced increased cerebral blood flow and disruption of the blood-brain barrier, which is a critical aspect of HACE pathophysiology, as discussed in the literature 1.

From the FDA Drug Label

Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by four mg every six hours intramuscularly until the symptoms of cerebral edema subside

  • High altitude cerebral edema is not explicitly mentioned in the provided drug labels.
  • The labels do discuss cerebral edema in general, but the specific context of high altitude is not addressed.
  • Therefore, no conclusion can be drawn regarding the use of dexamethasone for high altitude cerebral edema based on the provided information 2, 2.

From the Research

Definition and Symptoms of High Altitude Cerebral Edema

  • High altitude cerebral edema (HACE) is a rare and potentially fatal complication of traveling to high altitudes too quickly 3, 4.
  • Symptoms of HACE include disturbances of consciousness, psychiatric changes, confusion, and ataxia of gait, and can progress to deep coma 3.
  • HACE is often a complication of acute mountain sickness (AMS) or high altitude pulmonary edema (HAPE) 3, 5.

Pathophysiology of High Altitude Cerebral Edema

  • The current leading theory of HACE pathophysiology is that it is a vasogenic edema, resulting from disruption of the blood-brain barrier 3, 6.
  • HACE may also involve ionic edema, and speculation remains regarding the exact etiology of HACE and its relationship to AMS 6.
  • Cerebral vasodilation, increased intracranial blood volume, and concomitant intracranial fluid shifts may also contribute to the development of HACE 6.

Treatment and Prevention of High Altitude Cerebral Edema

  • Treatment of HACE typically involves descent, oxygen therapy, and steroids, with a greater emphasis on descent and steroids compared to other altitude illnesses 3, 5.
  • Prevention of HACE involves gradual acclimatization to high altitudes, and pharmacologic strategies such as acetazolamide and dexamethasone may also be effective 5, 7.
  • Management of HACE may also involve the use of medications such as nifedipine, sildenafil, and acetazolamide, although the evidence for these treatments is limited 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

High altitude cerebral edema.

High altitude medicine & biology, 2004

Research

High altitude cerebral edema.

Neurosurgery, 1986

Research

Advances in the Prevention and Treatment of High Altitude Illness.

Emergency medicine clinics of North America, 2017

Research

High-altitude cerebral edema: its own entity or end-stage acute mountain sickness?

Journal of applied physiology (Bethesda, Md. : 1985), 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.